ACRYLIC-CONTAINING NUCLEAR TRANSPORT MODULATORS AND APPLICATION THEREOF Russian patent published in 2025 - IPC C07D403/12 C07D401/12 C07D413/12 C07D471/10 C07D487/10 C07D498/10 C07D491/107 A61K31/4196 A61K31/397 A61K31/45 A61K31/496 A61K31/501 A61K31/513 A61K31/55 A61K31/4985 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formulas (1C):

(1C) or a pharmaceutically acceptable salt thereof, where: n is equal to 1; Y is selected from a group consisting of a bond, -CH₂-, -CO-, -SO₂-, and -COCON(R⁸)-; wherein R⁸ is H, or C1-C3 alkyl; and R⁷ is selected from the group consisting of H, C1-C3 alkyl, C3 cycloalkyl, and 6-member heteroaryl containing 1-2 N heteroatoms, optionally substituted with a halogen;

(1AA) or a pharmaceutically acceptable salt thereof, where: m is equal to 0, 1, 2 or 3; R^a, R^b, R^c and R^d are independently selected from a group consisting of H, halogen, OCH₂CF₃, OH, NMe₂, R³ and OR³; wherein R³ is C1-C3 alkyl group or C3 cycloalkyl group; or R^a and R^b together with a carbon atom bonded thereto, form a C3 cycloalkyl group or 4–6-membered non-aromatic heterocycle containing 1 N heteroatom, optionally substituted CH₃ or COCH₃; or R^c and R^d together with a carbon atom bonded to them, form a C3-C6 cycloalkyl group or 4–6-membered non-aromatic heterocycle containing 1 N or O heteroatom, optionally substituted CH₃ or COCH₃; or R^a (or R^b) and R^c (or R^d) together with the C-C bond bonded thereto, form C3-C6 cycloalkyl;

(1AB) or a pharmaceutically acceptable salt thereof, where: n is 1 or 2; R^e and R^f are independently selected from a group consisting of H, OCH₂CF₃, OCH₂CH₂OCH₃, O-CD₃, R³ and OR³; wherein R³ is C1-C3 alkyl, or C3 cycloalkyl;

(1AC) or a pharmaceutically acceptable salt thereof, where: M is -O-, -NR³- or -CO-, wherein R³ is C1-C3 alkyl or COCH₃; R^g, R^h, Rⁱ and R^j are H; or R^g and R^h together represent a -CO- group; or Rⁱ and R^j together represent a -CO- group, or Rⁱ and R^j together with the carbon atom bonded thereto form C3 cycloalkyl;

(1BA) or a pharmaceutically acceptable salt thereof, where: n is 1 or 2; Q is -CH₂- or -CO-; R⁹ is selected from the group consisting of H, C1-C3 alkyl, deuterated C1-C3 alkyl, C3-C6 cycloalkyl, amino-substituted C1-C3 alkylamino, C1-substituted C1-C3 alkyl, C3 substituted C1-C3 alkyl, 6-member heteroaryl and 5–7-member non-aromatic heterocycle containing 1 heteroatom N, optionally substituted with CH₃.

EFFECT: novel compounds which can be used to treat or prevent diseases associated with physiological conditions associated with the CRM1 protein are obtained.

7 cl, 2 dwg, 7 tbl, 108 ex